SCHEMBL8501511

SCHEMBL8501511

COc1cc2ccc(-c3cccc(-c4ccccc4)c3)nc2cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.57
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 3/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
PDGFRB P09619 4/20 0.55
PDGFRA P16234 4/20 0.55
GLA P06280 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
HPGD P15428 2/20 0.50
ACACA Q13085 1/20 0.50
LMNA P02545 1/20 0.50
TDO2 P48775 1/20 0.49
NQO2 P16083 1/20 0.47
EGFR P00533 1/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29501311 0.90 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL28596277 0.90 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL13870921 0.84 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL13870935 0.84 PDGFRB (0.61) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL21215819 0.78 BACE1 (0.47) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL21215930 0.76 RAB9A (0.43) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL14065141 0.76 RAB9A (0.56) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL21215928 0.76 RAB9A (0.43) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL4216248 0.76 RAB9A (0.56) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL13870939 0.76 KDM4E (0.55) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE36256-E ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-07-20 US disclosed
US-5795889-A INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-08-18 US disclosed
US-5656643-A QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-08-12 US disclosed
US-5646153-A INHIBITING ABNORMAL CELL PROLIFERATION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-08 US disclosed
US-5480883-A Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-01-02 US disclosed
US-5409930-A Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1995-04-25 US disclosed
EP-0584222-A4 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE POULENC RORER INT (US) 1994-07-06 EP disclosed
EP-0584222-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. RHONE POULENC RORER INT (US) 1994-03-02 EP disclosed
WO-1992020642-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-11-26 WO disclosed